The last two and half years have brought unprecedented changes to the world with the COVID-19 pandemic. In response to this challenge, the scientific community has mobilized on many fronts with advances in vaccines, diagnostics, treatments, pathology, immunology, virology, structural biology, cell biology, epidemiology and many other areas. However, many challenges still remain, particularly in the areas of long-term pathology, treatments, viral variants, and the development of broadly protective vaccines. To help facilitate interactions and highlight work from NIH/FDA investigators, the NIH COVID-19 scientific interest group is hosting our second virtual workshop for NIH/FDA staff. We look forward to your active participation to make this workshop a success during this challenging time.
When: December 15-16, 2022, 11am-5pm.
Where: Virtual
Who: YOU, NIH intramural and FDA researchers involved in COVID research and those who would like to learn more about COVID research.
What: Talks and flash talks from abstracts and some invited speakers
Submit your abstract and register at:
https://events.cancer.gov/ccr/covid19symposium
Abstract submission will open OCTOBER 11th and end OCTOBER 28.
Registration will stay open until full.
PLEASE NOTE THAT THE WORKSHOP IS ONLY OPEN TO THE NIH AND FDA.
Topics include:
- Animal Models
- Cell Biology
- Clinical features/outcomes
- Diagnostics
- Epidemiology
- Ethics
- Genetics/Genomics
- Health Disparities
- Immunology
- Long COVID/longterm sequelae
- Mental Health
- Structural Biology
- Systems Biology/computational
- Treatments
- Vaccines
- Virology
- Women and COVID
- And other exciting areas
We look forward to hearing about the great work going on at NIH and the FDA and hope to “see” you there. Please note that the virtual workshop will be limited to members of the NIH and FDA communities, so your active participation is highly encouraged.
Nihal Altan-Bonnet, NHLBI
Alex Compton, NCI
Surender Khurana, FDA
Emily Lee, NCATS
Veronique Nussenblatt, NIAID
Pamela Schwartzberg, NIAID
Kanal Singh, NIAID